Dyne Therapeutics, Inc. (NASDAQ:DYN) is one of the 13 Best Healthcare Stocks to Buy Under $10. In a report released on July 7 ...

The Ultimate Universe took Janet Van Dyne (the Wasp) and turned her into a villain, but it may have saved her life in the process.

Evercore ISI analyst Gavin Clark-Gartner lowered the firm’s price target on Dyne Therapeutics (DYN) to $41 from $46 and keeps an Outperform rating ...

The companies Insmed, Cidara Therapeutics, and Cogent Biosciences bagged the biggest biotech funding rounds overall in June ...

Shares of Dyne Therapeutics declined after the company commenced an underwritten public offering and said it had secured up to $275 million of debt financing. The stock fell 9.8% to $8.59 on Monday.

Dyne Therapeutics secures $275 million loan to advance treatments for myotonic dystrophy and Duchenne muscular dystrophy. Quiver AI Summary. Dyne Therapeutics, Inc. has announced a $275 million ...

Tesla shares dipped 4.6% to $303.13 in the pre-market trading session. TaxStatus is the only firm to provide the ...

WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases ...

Dyne also intends to grant the underwriters a 30-day option to purchase up to an additional $30,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by ...

WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically ...

WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases ...